Partnership milestone drives expansion and new opportunities

Tillotts Pharma AG marks a significant milestone in its business journey, celebrating 15 years of exceptional growth and collaboration as part of the Japanese Zeria Group. The company’s success story has led to valuable opportunities and strategic advancements, underpinned by its strong performance and expanding portfolio.

Since joining the Zeria Group in 2009, Tillotts has achieved remarkable double-digit growth, capitalising on its in-house developments and strategic in-licensing. In particular, the licensing of Dificlir™ for treating Clostridioides difficile infection (CDI) in 2020 has proven to be a transformative move, quadrupling the company's revenue and adding a life-saving product to its offerings.

Mr Sachiaki Ibe, Chairman and CEO of Zeria Pharmaceutical Co, Ltd, expressed his appreciation for Tillotts’ growth: “Tillotts has shown extraordinary performance over these 15 years, and I sincerely appreciate the significant contributions made to the Zeria Group. Our partnership has been strengthened over the years and has positively influenced the future trajectory of both Tillotts and Zeria. I extend my sincere gratitude to the entire Tillotts team for their dedication and look forward to continued growth for both Zeria and Tillotts through our collaborative efforts.”

Looking to the future, Tillotts Pharma continues to explore new business opportunities and avenues for growth. The company’s leadership in gastroenterology and infectious diseases has positioned it well for further expansion across Europe and into new international markets. Tillotts' partnership with Zeria has enabled it to utilise both operational expertise and market reach, strengthening its prospects for continued growth.

Thomas A. Tóth, CEO of Tillotts Pharma AG, reflected on the ongoing opportunities: “The long-standing partnership with Zeria fills us with great pride and gratitude for the mutual trust we have built over the years. Tillotts has evolved from a key player in IBD to a strong specialty pharma company, establishing ourselves as a leader in gastroenterology and infectious diseases. Our successes have allowed us to broaden our network of affiliates across Europe, with ambitions to grow beyond the continent in the near future.”

Zeria’s appreciation for Tillotts’ achievements reflects the value of their partnership, with opportunities for increased collaboration and mutual growth. As Tillotts Pharma expands its footprint and explores new therapeutic areas, it remains committed to delivering innovative solutions to patients worldwide.

More information online